US EditionLocus Cell's Zhubei Smart GMP Facility Secures First International Phase III CDMO Manufacturing MOU with Cambium Bio
- On September 29, 2025, Locus Cell and Australian company Cambium Bio entered into a Memorandum of Understanding for Phase III contract development and manufacturing services at Locus Cell’s advanced GMP facility located in Zhubei, Taiwan.
- The agreement arose as Cambium Bio entrusted Locus Cell with production responsibilities for its Elate Ocular therapy, currently in Phase III trials across Taiwan, the U.S., and Australia.
- Locus Cell’s Zhubei facility complies with FDA and GMP standards and integrates digital-enabled systems to ensure quality, stability, and cost-effective flexibility for clinical and commercial production.
- Chairman Jiunn-Rong Chiou called this Locus Cell’s first international Phase III CDMO project and a strong vote of confidence, while CEO Karolis Rosickas highlighted its rare capability in Asia.
- This MOU marks a key step for Locus Cell’s global expansion and strategic supply chain role, indicating its readiness to support worldwide pharmaceutical partners beyond the Middle East and Europe regions.
38 Articles
38 Articles
Locus Cell's Zhubei Smart GMP Facility Secures First International Phase III CDMO Manufacturing MOU with Cambium Bio
TAIPEI, Sept. 29, 2025 /PRNewswire/ -- Locus Cell (TWSE: 6891), a leading regenerative medicine CDMO in Taiwan, announced it has signed a Memorandum of Understanding (MOU) with Australia-based Cambium Bio (ASX: CMB). Under the agreement, Cambium will entrust Locus Cell with the contract development and manufacturing (CDMO) of Elate Ocular® -related. Elate Ocular®, a Phase III dry eye disease therapy currently under clinical trials in Taiwan, the…
Locus Cell Partners with Cambium Bio for Phase III Regenerative Medicine Manufacturing at Zhubei Facility
Locus Cell, a Taiwan-based regenerative medicine contra […] The post Locus Cell Partners with Cambium Bio for Phase III Regenerative Medicine Manufacturing at Zhubei Facility first appeared on GeneOnline News. The post Locus Cell Partners with Cambium Bio for Phase III Regenerative Medicine Manufacturing at Zhubei Facility appeared first on GeneOnline News.
Coverage Details
Bias Distribution
- 72% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
